Surgical Resection of the Primary Tumor in Patients with Metastatic Pheochromocytoma and Sympathetic Paraganglioma: Impact on Survival and Quality of Life

Alejandro Roman-Gonzalez1; Montserrat Ayala-Ramirez2; Ioannis Christaki3; Wei Qiu3; Steven Waguespack2; Mouhammed Habra2; Nancy Perrier3; Camilo Jimenez2

1Department of Endocrinology, Hospital Universitario San Vicente Fundacion-Universidad de Antioquia. Medellin, Colombia and Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas
2Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas
3Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas

Background: Patients with metastatic pheochromocytoma and paraganglioma (PPG) exhibit a decreased overall survival. Current treatments for these tumors are not curative. The role of surgical resection of the primary tumor in patients with metastatic disease is still to be determined.

Methods: We performed a retrospective of MD Anderson Cancer Center database of patients with metastatic pheochromocytoma and paraganglioma. Demographic, clinical, biochemical, imaging, and pathological variables were analyzed.

Results: There were 113 patients with metastatic PPG; 89 had surgical removal of the primary tumor. 53 patients had synchronous metastases; of these 33 had resection of the primary tumor. The median diameter of the primary tumor in the whole cohort was 8.45 centimeters (range 1.90-24 cms).
Survival rates were longer in patients who underwent removal of the primary tumor when compared with patients who did not undergo resection (148 months, 95% CI 112.7-183.2 vs 36 months, 95% CI 27.2-44.8; p<0.001). In patients with synchronous metastases treated with surgery for the primary tumor, the survival rates were longer that in patients that were not treated with surgery (85 months, 95% CI 64.5 – 104.5 vs 36 months, 95% CI 29.7 – 42.3; p<0.001). No differences in age, race, primary tumor size or genetic background were noted in these cohorts. Survival rates in patients with metastatic disease were independent of the location of the primary tumor. In patients with hormonally active tumors treated with primary tumor resection, the symptoms of catecholamine excess including hypertension improved. Tumor burden rather than hormonal secretion is a more important determinant of overall survival in patients hormonally active metastatic PPG.

Conclusions: Resection of the primary tumor in patients with metastatic PPG is associated with an improved overall survival. In patients with hormonally active tumors, surgical resection is associated with better blood pressure control and symptom improvement.

Corresponding author: Nancy D. Perrier, Chief, Section of Surgical Endocrinology, Department of Surgical Oncology, M.D. Anderson Cancer Center, 1400 Pressler Street, FCT 17.6014, Unit 1484, Houston, Texas 77030-4009 Office Phone: 713 794-1345, Office Fax: 713 563-5727, Email: nperrier@mdanderson.org